J McKendrick

699 total citations
24 papers, 525 citations indexed

About

J McKendrick is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, J McKendrick has authored 24 papers receiving a total of 525 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 7 papers in Surgery. Recurrent topics in J McKendrick's work include Lung Cancer Treatments and Mutations (7 papers), Colorectal Cancer Treatments and Studies (6 papers) and Cancer Treatment and Pharmacology (4 papers). J McKendrick is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Colorectal Cancer Treatments and Studies (6 papers) and Cancer Treatment and Pharmacology (4 papers). J McKendrick collaborates with scholars based in Australia, United Kingdom and United States. J McKendrick's co-authors include P. Koralewski, Guy van Hazel, Chris Twelves, Werner Scheithauer, Howard A. Burris, Jean A. Maroun, Pilar García‐Alfonso, J. Załuski, W. Ivon Burns and Jerzy Tujakowski and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

J McKendrick

22 papers receiving 498 citations

Peers

Countries citing papers authored by J McKendrick

Since Specialization

Citations

This map shows the geographic impact of J McKendrick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J McKendrick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J McKendrick more than expected).

Fields of papers citing papers by J McKendrick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J McKendrick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J McKendrick. The network helps show where J McKendrick may publish in the future.

Co-authorship network of co-authors of J McKendrick

This figure shows the co-authorship network connecting the top 25 collaborators of J McKendrick. A scholar is included among the top collaborators of J McKendrick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J McKendrick. J McKendrick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer 2021 ·Current Problems in Cancer ·(unknown), (unknown), (unknown), (unknown), (unknown), Rachel Wong, (unknown), Lucy Gately, (unknown), (unknown), Suzanne Kosmider, Jeanne Tie, (unknown), Justin Yeung, Ross Jennens, Belinda Lee, J McKendrick, Lyn‐li Lim, Adnan Khattak, Peter Gibbs	1
2	Identification of Statin Intolerance: Results From A Survey of Clinicians in Taiwan 2016 ·Value in Health ·(unknown), J McKendrick, (unknown), (unknown), (unknown), Ricardo Dent, (unknown), Alberico L. Catapano, Paul Oh, (unknown), (unknown)	0
3	A Principal Component Analysis of Overall Survival Outcomes and List Prices of Oncology Drugs in Europe 2016 ·Value in Health ·(unknown), Casey Quinn, J McKendrick, M Aristides	0
4	Management of Patients with Statin Intolerance in Japan, South Korea and Taiwan: Comparison of Results From A Clinician Survey 2016 ·Value in Health ·(unknown), J McKendrick, (unknown), (unknown), G. Kees Hovingh, Ricardo Dent, (unknown), Alberico L. Catapano, Paul Oh, (unknown), (unknown)	1
5	Phase II trial evaluating the feasibility of interdigitating folfox with chemoradiotherapy in locally advanced and metastatic rectal cancer 2014 ·British Journal of Cancer ·Michael Michael, Sarat Chander, J McKendrick, John Mackay, Malcolm Steel, Rodney J. Hicks, Alexander G. Heriot, Trevor Leong, Prasad Cooray, Michael Jefford, John Zalcberg, Mathias Bressel, Bev McClure, Sam Ngan	5
6	Sensitivity Analyses of Progression-Free Survival (PFS) of Aflibercept-Folfiri Versus Placebo-Folfiri in Metastatic Colorectal Cancer (MCRC): Results from the Velour Study 2012 ·Annals of Oncology ·Eric Van Cutsem, Josep Tabernero, Radek Lakomý, Jana Prausová, Paul Ruff, Vladimir Moiseyenko, D. Ferry, Emmanuelle Boëlle, J McKendrick, Carmen J. Allegra	1
7	Results From VELOUR, a Phase 3 Study of Aflibercept (A) Versus Placebo (pbo) in Combination with FOLFIRI for the Treatment of Patients (pt) with Previously Treated Metastatic Colorectal Cancer (MCRC) 2011 ·European Journal of Cancer ·Josep Tabernero, Eric Van Cutsem, Radek Lakomý, Jana Prausová, Paul Ruff, Guy van Hazel, Vladimir Moiseyenko, D. Ferry, J McKendrick, Karen Soussan-Lazard, Emmanuelle Boëlle, Carmen J. Allegra	25
8	First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma 2008 ·Annals of Oncology ·Bohuslav Melichar, P. Koralewski, Alain Ravaud, A Płużańska, Sergio Bracarda, Cezary Szczylik, Christine Chevreau, M. Filipek, R. Delva, Emmanuel Sevin, Sylvie Négrier, J McKendrick, Armando Santoro, Pavel Pisa, Bernard Escudier	71
9	A comparison of quality of life in patients with T3 rectal cancer receiving short course versus long course preoperative radiation. A Trans-Tasman Radiation Oncology Group Trial (TROG 01.04) 2008 ·Journal of Clinical Oncology ·Sue Anne McLachlan, Rebecca Fisher, Bev McClure, J. Beresford, J McKendrick, (unknown), (unknown), B. Burmeister, (unknown), Sam Ngan	4
10	Lack of evidence of disease contamination in ovarian tissue harvested for cryopreservation from patients with Hodgkin lymphoma and analysis of factors predictive of oocyte yield 2006 ·British Journal of Cancer ·Tara Seshadri, Debra A. Gook, Stephen Lade, Andrew Spencer, Andrew Grigg, Karin Tiedemann, J McKendrick, Philip B. Mitchell, C. Stern, John F. Seymour	58
11	Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation 2005 ·Bone Marrow Transplantation ·Andrew Spencer, Noemi Horvath, John Gibson, H. Miles Prince, Richard Herrmann, John Bashford, David Joske, Andrew Grigg, J McKendrick, I Prosser, Ray M. Lowenthal, (unknown), K Taylor, (unknown)	55
12	A phase I trial of high-dose palliative radiotherapy plus concurrent weekly Vinorelbine and Cisplatin in patients with locally advanced and metastatic NSCLC 2005 ·British Journal of Cancer ·Michalis Michael, A. Wirth, (unknown), Michael MacManus, Danny Rischin, Linda Mileshkin, Benjamin Solomon, J McKendrick, A. Milner	12
13	Pharmacoeconomic analysis of Capecitabine in the adjuvant setting. Results from the X-ACT trial comparing capecitabine with 5-FU/LV in patients with Dukes' C colon cancer 2004 ·Annals of Oncology ·(unknown), C.J. Twelves, J McKendrick, Oscar Bertetto, Fraser P. Coxon, Eduardo Díaz‐Rubio, P. Dufour, (unknown), Werner Scheithauer, Howard A. Burris	7
14	Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial 2003 ·Annals of Oncology ·Werner Scheithauer, J McKendrick, S. Begbie, Markus Borner, W. Ivon Burns, Howard A. Burris, Jim Cassidy, Duncan I. Jodrell, P. Koralewski, E.L. Levine, Norbert Marschner, Jean A. Maroun, Pilar García‐Alfonso, Jerzy Tujakowski, Guy van Hazel, A. Wong, J. Załuski, Chris Twelves	222
15	An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study Ann Oncol 2002; 13: 1264–1274 2002 ·Annals of Oncology ·G.M. Mead, Matthew R. Sydes, Jan Walewski, A. Grigg, Christian S. R. Hatton, (unknown), C. Guarnaccia, Michael Lewis, J McKendrick, SP Stenning, (unknown)	6
16	Economic evaluation of Gemzar/cisplatin relative to other cisplatin based treatments for non small cell lung (NSCLC) cancer in the UK 2001 ·European Journal of Cancer ·N. Botwood, J McKendrick, M Aristides, (unknown), N Maniadakis, Wolfgang Wein, D. Stephenson	1
17	CN4: ECONOMIC EVALUATION OF GEMZAR/CISPLATIN RELATIVE TO OTHER CISPLATIN BASED TREATMENTS FOR NON SMALL CELL LUNG (NSCLC) CANCER IN THE UK 2001 ·Value in Health ·N. Botwood, J McKendrick, M Aristides, (unknown), N Maniadakis, Wolfgang Wein, D. Stephenson	1
18	High dose intensity combination chemotherapy for advanced epithelial ovarian carcinoma: results of a pilot study 1990 ·British Journal of Cancer ·(unknown), J McKendrick, (unknown), J. M. A. Whitehouse, (unknown)	2
19	Involvement of the ileocaecal region by non-Hodgkin's lymphoma in adults: clinical features and results of treatment 1989 ·British Journal of Cancer ·(unknown), (unknown), D H Wright, J McKendrick, (unknown), (unknown), J. M. A. Whitehouse	13
20	ChlVPP chemotherapy in advanced Hodgkin's disease 1989 ·European Journal of Cancer and Clinical Oncology ·J McKendrick, Graham M. Mead, John Sweetenham, (unknown), Christopher J. Williams, R. D. H. Ryall, J. M. A. Whitehouse	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact